Javascript is disabled or is not supported by your browser. Please upgrade your browser or enable Javascript to navigate the interface properly.

venBio Select Advisor

Latest statistics and disclosures from Avoro Capital Advisors's latest quarterly 13F-HR filing:

Top 5 stock holdings are UTHR, ASND, MDGL, KRYS, ARGX, and represent 53.46% of Avoro Capital Advisors's stock portfolio.
Added to shares of these 10 stocks: UTHR (+$240M), CYTK (+$220M), DMRA (+$98M), DFTX (+$95M), TERN (+$71M), AVTX (+$21M), XENE (+$21M), RVMD (+$17M), OCUL (+$13M), ARGX (+$7.3M).
Started 4 new stock positions in DFTX, CYTK, AVTX, DMRA.
Reduced shares in these 10 stocks: Avidity Biosciences Ord (-$394M), , CNTA (-$124M), MNMD (-$67M), PTCT (-$52M), ORKA (-$40M), APGE (-$38M), ASND (-$23M), SLNO (-$20M), .
Sold out of its positions in APGE, Avidity Biosciences Ord, INCY, MNMD, ORKA, PTCT, XBI.
Avoro Capital Advisors was a net seller of stock by $-232M.
Avoro Capital Advisors has $10B in assets under management (AUM), dropping by -1.36%.
Central Index Key (CIK): 0001633313

Tip: Access up to 7 years of quarterly data

Positions held by venBio Select Advisor consolidated in one spreadsheet with up to 7 years of data

Download as csv

Download as Excel

Portfolio Holdings for Avoro Capital Advisors

Avoro Capital Advisors holds 30 positions in its portfolio as reported in the March 2026 quarterly 13F filing

Company (Ticker)	Portfolio Weight	Valued At	Change in Shares	Share Count	Share Price
United Therapeutics Corp Common (UTHR)	17.8	$1.8B	+15%	3.0M	592.98	View chart
Ascendis Pharma Sponsored ADR (ASND)	11.5	$1.2B		5.1M	228.73	View chart
Madrigal Pharmaceuticals Common (MDGL)	9.5	$952M		1.8M	523.47	View chart
Krystal Biotech Common (KRYS)	7.4	$746M		2.9M	258.32	View chart
Argenx Se Sponsored ADR (ARGX)	7.3	$730M		1.0M	730.25	View chart
Arrowhead Pharmaceuticals Common (ARWR)	6.7	$671M		11M	62.70	View chart
Kymera Therapeutics Common (KYMR)	6.2	$623M		7.5M	83.29	View chart
Apellis Pharmaceuticals Common (APLS)	4.9	$492M		12M	40.23	View chart
Centessa Pharmaceuticals Sponsored Ads (CNTA)	4.5	$454M	-21%	11M	39.72	View chart
Xenon Pharmaceuticals Common (XENE)	3.3	$336M	+6%	5.8M	58.15	View chart
Structure Therapeutics Sponsored Ads (GPCR)	3.1	$316M		6.6M	48.20	View chart
Terns Pharmaceuticals Common (TERN)	3.0	$300M	+30%	5.7M	52.72	View chart
Vera Therapeutics Common (VERA)	2.4	$237M		5.9M	40.23	View chart
Revolution Medicines Common (RVMD)	2.3	$228M	+8%	2.3M	97.25	View chart
Cytokinetics Common (CYTK)	2.2	$220M	NEW	3.3M	65.91	View chart
Ocular Therapeutix Common (OCUL)	1.0	$104M	+14%	12M	8.47	View chart
Damora Therapeutics Common (DMRA)	1.0	$98M	NEW	3.8M	25.90	View chart
Uniqure Nv Common (QURE)	1.0	$97M	-3%	6.0M	16.35	View chart
Taysha Gene Therapies Common (TSHA)	1.0	$97M		22M	4.47	View chart
Definium Therapeutics Common (DFTX)	0.9	$95M	NEW	5.0M	18.90	View chart
Soleno Therapeutics Common (SLNO)	0.8	$77M	-20%	2.3M	33.48	View chart
Celcuity Common Call Option (CELC)	0.5	$55M	+14%	3.6M	15.25	View chart
Alkermes Common (ALKS)	0.4	$42M	-14%	1.2M	35.36	View chart
Septerna Common (SEPN)	0.3	$32M		1.3M	24.03	View chart
Viridian Therapeutics Common (VRDN)	0.3	$29M		1.5M	19.56	View chart
Gh Research Ordinary Shares (GHRS)	0.3	$25M		1.8M	14.06	View chart
Avalo Therapeutics Common (AVTX)	0.2	$21M	NEW	1.4M	14.93	View chart
Lexeo Therapeutics Common (LXEO)	0.1	$11M	-43%	1.9M	5.74	View chart
Whitehawk Therapeutics Common (WHWK)	0.1	$9.8M		2.8M	3.45	View chart
Mannkind Corp Common (MNKD)	0.1	$5.4M	-50%	2.2M	2.45	View chart

Past Filings by Avoro Capital Advisors

SEC 13F filings are viewable for Avoro Capital Advisors going back to 2014

Avoro Capital Advisors 2026 Q1 filed May 15, 2026
Avoro Capital Advisors 2025 Q4 restated filed March 16, 2026
Avoro Capital Advisors 2025 Q4 filed Feb. 17, 2026
Avoro Capital Advisors 2025 Q3 filed Nov. 14, 2025
Avoro Capital Advisors 2025 Q2 filed Aug. 14, 2025
Avoro Capital Advisors 2025 Q1 filed May 15, 2025
Avoro Capital Advisors 2024 Q4 filed Feb. 14, 2025
Avoro Capital Advisors 2024 Q3 filed Nov. 14, 2024
Avoro Capital Advisors 2024 Q2 filed Aug. 14, 2024
Avoro Capital Advisors 2024 Q1 filed May 15, 2024
Avoro Capital Advisors 2023 Q4 filed Feb. 14, 2024
Avoro Capital Advisors 2023 Q3 filed Nov. 14, 2023
Avoro Capital Advisors 2023 Q2 filed Aug. 14, 2023
Avoro Capital Advisors 2023 Q1 filed May 15, 2023
Avoro Capital Advisors 2022 Q4 filed Feb. 14, 2023
Avoro Capital Advisors 2022 Q3 filed Nov. 14, 2022

View all past filings

Disclaimers: stockzoa.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on stockzoa.com represent a recommendation to purchase or sell a stock. The information on this site is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall stockzoa.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content available on stockzoa.com, or relating to the use of, or inability to use, stockzoa.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.

Fund Directory: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X-Z